Press Releases Keyword Search Year None20262025202420232022202120202019201820172016201520142013 December 9, 2019 Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia November 12, 2019 Editas Medicine Announces Third Quarter 2019 Results and Update November 12, 2019 Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases November 5, 2019 Editas Medicine to Host Conference Call Discussing Third Quarter 2019 Results and Corporate Update October 28, 2019 Editas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer October 15, 2019 Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases October 7, 2019 Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines October 1, 2019 Editas Medicine to Participate in Upcoming Investor Conferences August 29, 2019 Editas Medicine to Participate in Upcoming Investor Conferences August 6, 2019 Editas Medicine Announces Second Quarter 2019 Results and Update Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
December 9, 2019 Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia
November 12, 2019 Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases
November 5, 2019 Editas Medicine to Host Conference Call Discussing Third Quarter 2019 Results and Corporate Update
October 15, 2019 Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases
October 7, 2019 Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines
